Scientists at the University of Oxford, led by Professor Ahmed Ahmed, are designing OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 for the study over the next three years to support lab research into the vaccine.
In this study, the CRUK-funded researchers will establish the targets for the vaccine. They will find out which proteins on the surface of early-stage ovarian cancer cells are most strongly recognised by the immune system and how effectively the vaccine kills mini-models of ovarian cancer called organoids.
If this research is successful, work will then begin on clinical trials of the vaccine. The hope is that in the future, women could be offered this vaccine to prevent ovarian cancer in the first place.
Read the full story on the MRC Weatherall Institute of Molecular Medicine (MRC WIMM) website.
more recommended stories
CDI Test Shows Early Detection Potential in Alzheimer’sBreakthrough Study Highlights Brain Blood Flow.
Prenatal Chlorpyrifos Exposure and Pediatric Brain ChangesA Growing Concern in Pediatric Neurodevelopment.
Valve Deterioration After TAVI: New Research InsightsThe Growing Role of TAVI in.
FAST Walking Shows Promise in Post-Stroke RehabStroke remains one of the leading.
Legionnaires’ Disease Long-Term Effects on Patient RecoveryPersistent Symptoms and Post-Acute Infection Syndromes.
Brisk Walking: A 15-Minute Daily Habit That Reduces Mortality in Underserved PopulationsA powerful yet simple intervention A.
Vaping and Teen Smoking: UK Study Warns of Rising RisksA new study published in Tobacco.
Targeting Cancer Cell Memory Boosts ChemotherapyResearchers double chemotherapy effectiveness through chromatin.
PFAS Exposure Linked to Increased Type 2 Diabetes RiskInvestigating the Metabolic Impact of Forever.
Gecko-Inspired Nanoparticles Offer New Direction in Localized Cancer TherapyNature-Inspired Nanoparticles Deliver Precision Chemotherapy Researchers.
Leave a Comment